BioLineRx Ltd. — Board/Management Information 2016

Aug 29, 2016

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2016

BioLineRx Ltd.

_______________________

(Translation of registrant's name into English) _______________________

2 HaMa'ayan Street Modi'in 7177871, Israel (Address of Principal Executive Offices)

_______________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☑ Form 40-F ☐

Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2 (b) under the Securities Exchange Act of 1934:

Yes ☐ No ☑

The Registrant hereby announces the departure of Arnon Aharon, M.D., its Chief Medical Officer, effective November 30, 2016. The Registrant is currently meeting with potential candidates in order to fill the position.

This report on Form 6-K is hereby incorporated by reference into all effective registration statements filed by the Company under the Securities Act of 1933.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

BioLineRx Ltd.

By: /s/ Philip Serlin

Philip Serlin Chief Financial and Operating Officer

Dated: August 29, 2016